BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25085456)

  • 1. Dosimetry modeling for focal high-dose-rate prostate brachytherapy.
    Mason J; Al-Qaisieh B; Bownes P; Thwaites D; Henry A
    Brachytherapy; 2014; 13(6):611-7. PubMed ID: 25085456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetry Modeling for Focal Low-Dose-Rate Prostate Brachytherapy.
    Al-Qaisieh B; Mason J; Bownes P; Henry A; Dickinson L; Ahmed HU; Emberton M; Langley S
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):787-93. PubMed ID: 25936808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemi-gland focal low dose rate prostate brachytherapy: An analysis of dosimetric outcomes.
    Laing R; Franklin A; Uribe J; Horton A; Uribe-Lewis S; Langley S
    Radiother Oncol; 2016 Nov; 121(2):310-315. PubMed ID: 27814981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focal high-dose-rate brachytherapy: a dosimetric comparison of hemigland vs. conventional whole-gland treatment.
    Kamrava M; Chung MP; Kayode O; Wang J; Marks L; Kupelian P; Steinberg M; Park SJ; Demanes DJ
    Brachytherapy; 2013; 12(5):434-41. PubMed ID: 23406987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From whole gland to hemigland to ultra-focal high-dose-rate prostate brachytherapy: A dosimetric analysis.
    Banerjee R; Park SJ; Anderson E; Demanes DJ; Wang J; Kamrava M
    Brachytherapy; 2015; 14(3):366-72. PubMed ID: 25680768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose-rate prostate brachytherapy consistently results in high quality dosimetry.
    White EC; Kamrava MR; Demarco J; Park SJ; Wang PC; Kayode O; Steinberg ML; Demanes DJ
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):543-8. PubMed ID: 22652111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approach of ultra-focal brachytherapy for low- and intermediate-risk prostate cancer with custom-linked I-125 seeds: A feasibility study of optimal dose coverage.
    Brun T; Bachaud JM; Graff-Cailleaud P; Malavaud B; Portalez D; Popotte C; Aziza R; Lusque A; Filleron T; Ken S
    Brachytherapy; 2018; 17(3):544-555. PubMed ID: 29525514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of clinically relevant dosimetric parameters to contouring uncertainty in postimplant dosimetry of low-dose-rate prostate permanent seed brachytherapy.
    Mashouf S; Safigholi H; Merino T; Soliman A; Ravi A; Morton G; Song WY
    Brachytherapy; 2016; 15(6):774-779. PubMed ID: 27720310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of source batch S dispersion on dosimetry for prostate cancer treatment with permanent implants.
    Nuñez-Cumplido E; Perez-Calatayud J; Casares-Magaz O; Hernandez-Armas J
    Med Phys; 2015 Aug; 42(8):4933-40. PubMed ID: 26233219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monte Carlo investigation of I-125 interseed attenuation for standard and thinner seeds in prostate brachytherapy with phantom validation using a MOSFET.
    Mason J; Al-Qaisieh B; Bownes P; Henry A; Thwaites D
    Med Phys; 2013 Mar; 40(3):031717. PubMed ID: 23464312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel urethral sparing technique for high-dose-rate prostate brachytherapy after transurethral resection of the prostate.
    Kunogi H; Cunha JAM; Chang AJ; Gadzinski AJ; Shinohara K; Hsu IC
    Brachytherapy; 2017; 16(6):1113-1118. PubMed ID: 28869143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptation of the CVT algorithm for catheter optimization in high dose rate brachytherapy.
    Poulin E; Fekete CA; Létourneau M; Fenster A; Pouliot J; Beaulieu L
    Med Phys; 2013 Nov; 40(11):111724. PubMed ID: 24320432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.
    Kishan AU; Park SJ; King CR; Roberts K; Kupelian PA; Steinberg ML; Kamrava M
    Br J Radiol; 2015; 88(1056):20150658. PubMed ID: 26463234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate.
    Hermesse J; Biver S; Jansen N; Lenaerts E; Nickers P
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):269-76. PubMed ID: 19775833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
    Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
    Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
    J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focal prostate brachytherapy with (103)Pd seeds.
    Butler WM; Merrick GS
    Phys Med; 2016 Mar; 32(3):459-64. PubMed ID: 27053451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of catheter displacement and anatomical variations on the dose distribution in MRI-guided focal HDR brachytherapy for prostate cancer.
    Maenhout M; van der Voort van Zyp JRN; Borot de Battisti M; Peters M; van Vulpen M; van den Bosch M; Moerland MA
    Brachytherapy; 2018; 17(1):68-77. PubMed ID: 28579419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [High-dose brachytherapy for prostate cancer in real time using 192-IR (specifics of dosimetric planning)].
    Novikov SN; Kanaev SV; Novikov RV; Iliin ND; Gotovchikova MY
    Vopr Onkol; 2015; 61(1):130-6. PubMed ID: 26016159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
    Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.